NEW YORK (GenomeWeb News) - The School of Medicine and Dentistry at Barts and The London, a UK-based hospital teaching trust, has acquired a Roche 454 Genome Sequencer FLX as well as Roche NimbleGen sequence capture array technology, Roche said this week.
The school’s cancer genomics group, led by Brian Young, plans to use the system to study genetic changes involved in the development of leukemia. The researchers plan to link the sequence information to an existing clinical and cytogenetic database to investigate the relationship between genetic changes and clinical features of the disease.
The researchers expect that the new data could have implications for the future therapy and clinical outcome of hematological malignancies.
Using the Roche NimbleGen arrays, the researchers plan to capture a number of genes, including those known to be mutated in acute myelogenous leukemia, such as FLT3 and MLL, and characterize putative mutation targets by SNP genotype analysis. They also plan to analyze full sequences of mutated genes, including introns, using the GS FLX.
The scientists also want to study patterns of microRNA expression in AML and compare them to known gene expression profiles for other leukemia subtypes.
In addition, they plan to use paired-end sequencing to study microdeletions, a type of genetic abnormality that appears to be a characteristic feature of leukemias.